

Hepatitis C Tracking Data

(FY2019 Appropriation Act - Public Act 207 of 2018)

March 1, 2019

Sec. 1878. By March 1 of the current fiscal year, the department shall provide a report to the senate and house appropriations subcommittees on the department budget, the senate and house fiscal agencies, the senate and house policy offices, and the state budget office on hepatitis C tracking data. At a minimum, the report shall include information on the following for individuals treated with Harvoni or any other treatment used to cure hepatitis C during the current fiscal year or a previous fiscal year:

(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

(b) The total cost of treatment.

(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

(d) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.

(e) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.



Hepatitis C Tracking Data

(FY2019 Appropriation Act - Public Act 207 of 2018)

(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

In Fiscal Year 2017-2018, a total of 844 people were treated through traditional Medicaid and 1,050 people were treated through the Healthy Michigan Plan, for a grand total of 1,894 individuals.

(b) The total cost of treatment.

In Fiscal Year 2017-2018, a total of \$106,471,523 was spent on drugs designed to cure Chronic Hepatitis C.

(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.

In Fiscal Year 2017-2018, \$49,615,550 was spent on those treated through traditional Medicaid, while \$56,855,973 was spent on those treated through the Healthy Michigan Plan.

(d) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment & (e) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.ⁱ

To calculate the cure and reinfection rates for those receiving these treatments, practitioners who treated 2,126 patients with paid claims for these drugs from October 1, 2016 through September 30, 2017 were surveyed. This population was chosen because there would be enough time for all the necessary tests to be given to determine whether the individuals were cured. Of the 2,126 that were treated only 1,124 beneficiaries completed at least part of the survey and only 561 gave complete responses. We use those 561 in the analysis below. The overall cure rate was 99.5%, and the reinfection rate is 0.9%.

- Cure Rates

- By Metavir Score

- F4: 99.5%
 - F3: 99.1%
 - F2: 99.4%
 - F1: 100.0%
 - F0: 100.0%

- By Genotype

- 1a: 99.4%
 - 1b: 98.6%
 - 1 (subtype unknown or both A and B): 100.0%
 - 2: 100.0%
 - 3: 100.0%
 - 4: 100.0%
 - Other: 100.0%

Hepatitis C Tracking Data

(FY2019 Appropriation Act - Public Act 207 of 2018)

- By Medicaid Match Rate
 - Traditional Medicaid: 99.2%
 - HMP: 99.7%
 - Individuals who changed coverage between Traditional Medicaid and HMP: 100.0%
- By Drugs Used During Treatment
 - Harvoni: 99.2%
 - Epclusa: 100.0%
 - Zepatier: 100.0%
 - Viekira Pak: 100.0%
 - Technivie: 100.0%
 - Daklinza/Sovaldi: 100.0%
 - Harvoni/Vosevi: 100.0%
 - Mavyret: 100.0%
 - Epclusa/Vosevi: 100.0%
 - Harvoni/Zepatier: 100.0%
- Reinfection Rates
 - By Metavir Score
 - F4: 0.5%
 - F3: 2.7%
 - F2: 0.6%
 - F1: 0.0%
 - F0: 0.0%
 - By Genotype
 - 1a: 0.1%
 - 1b: 1.4%
 - 1 (subtype unknown or both A and B): 0.0%
 - 2: 0.0%
 - 3: 1.3%
 - 4: 0.0%
 - Other: 0.0%
 - By Medicaid Match Rate
 - Traditional Medicaid: 1.5%
 - HMP: 0.3%
 - Individuals who changed coverage between Traditional Medicaid and HMP: 0.0%

Hepatitis C Tracking Data

(FY2019 Appropriation Act - Public Act 207 of 2018)

- By Drugs Used During Treatment
 - Harvoni: 1.0%
 - Epclusa: 0.8%
 - Zepatier: 0.0%
 - Viekira Pak: 0.0%
 - Technivie: 0.0%
 - Daklinza/Sovaldi: 0.0%
 - Harvoni/Vosevi: 0.0%
 - Mavyret: 0.0%
 - Epclusa/Vosevi: 0.0%
 - Harvoni/Zepatier: 0.0%

¹ At this time, surveys detailing the cure and reinfection rates broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment for Fiscal Year 2017-2018 have not been returned to the department but will be published once available.